Molecules and Cells

  • 제43권2호
  • /
  • Pages.97-98
  • /
  • 2020
  • /
  • 1016-8478(pISSN)
  • /
  • 0219-1032(eISSN)
한국분자세포생물학회 (Korean Society for Molecular and Cellular Biology)
권호 표지
DOI QR코드

DOI QR Code

Tour d'Horizon of Recent Advances in RUNX Family Gene Research

  • Bae, Suk-Chul (Department of Biochemistry, College of Medicine, Chungbuk National University)
  • 투고 : 2019.12.20
  • 심사 : 2019.12.20
  • 발행 : 2020.02.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Bellissimo, D.C. and Speck, N.A. (2017). RUNX1 mutations in inherited and sporadic leukemia. Front. Cell Dev. Biol. 5, 111. https://doi.org/10.3389/fcell.2017.00111
  2. Blyth, K., Vaillant, F., Hanlon, L., Mackay, N., Bell, M., Jenkins, A., Neil, J.C., and Cameron, E.R. (2006). RUNX2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res. 66, 2195-2201. https://doi.org/10.1158/0008-5472.CAN-05-3558
  3. Ferrari, N., McDonald, L., Morris, J.S., Cameron, E.R., and Blyth, K. (2013). RUNX2 in mammary gland development and breast cancer. J. Cell. Physiol. 228, 1137-1142. https://doi.org/10.1002/jcp.24285
  4. Ito, Y., Bae, S.C., and Chuang, L.S. (2015). The RUNX family: developmental regulators in cancer. Nat. Rev. Cancer 15, 81-95. https://doi.org/10.1038/nrc3877
  5. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R.T., Gao, Y.H., Inada, M., et al. (1997). Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89, 755-764. https://doi.org/10.1016/S0092-8674(00)80258-5
  6. Lee, B., Thirunavukkarasu, K., Zhou, L., Pastore, L., Baldini, A., Hecht, J., Geoffroy, V., Ducy, P., and Karsenty, G. (1997). Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat. Genet. 16, 307-310. https://doi.org/10.1038/ng0797-307
  7. Lee, C.W., Chuang, L.S., Kimura, S., Lai, S.K., Ong, C.W., Yan, B., Salto-Tellez, M., Choolani, M., and Ito, Y. (2011). RUNX3 functions as an oncogene in ovarian cancer. Gynecol. Oncol. 122, 410-417. https://doi.org/10.1016/j.ygyno.2011.04.044
  8. Lee, J.W., Kim, D.M., Jang, J.W., Park, T.G., Song, S.H., Lee, Y.S., Chi, X.Z., Park, I.Y., Hyun, J.W., Ito, Y., et al. (2019a). RUNX3 regulates cell cycle-dependent chromatin dynamics by functioning as a pioneer factor of the restrictionpoint. Nat. Commun. 10, 1897. https://doi.org/10.1038/s41467-019-09810-w
  9. Lee, J.W., Park, T.G., and Bae, S.C. (2019b). Involvement of RUNX and BRD family members in restriction point. Mol. Cells 42, 836-839. https://doi.org/10.14348/molcells.2019.0256
  10. Lee, Y.S., Lee, J.W., Jang, J.W., Chi, X.Z., Kim, J.H., Li, Y.H., Kim, M.K., Kim, D.M., Choi, B.S., Kim, E.G., et al. (2013). RUNX3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell 24, 603-616. https://doi.org/10.1016/j.ccr.2013.10.003
  11. Li, Q.L., Ito, K., Sakakura, C., Fukamachi, H., Inoue, K., Chi, X.Z., Lee, K.Y., Nomura, S., Lee, C.W., Han, S.B., et al. (2002). Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109, 113-124. https://doi.org/10.1016/S0092-8674(02)00690-6
  12. Mundlos, S., Otto, F., Mundlos, C., Mulliken, J.B., Aylsworth, A.S., Albright, S., Lindhout, D., Cole, W.G., Henn, W., Knoll, J.H., et al. (1997). Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 89, 773-779. https://doi.org/10.1016/S0092-8674(00)80260-3
  13. Okuda, T., van Deursen, J., Hiebert, S.W., Grosveld, G., and Downing, J.R. (1996). AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84, 321-330. https://doi.org/10.1016/S0092-8674(00)80986-1
  14. Otto, F., Thornell, A.P., Crompton, T., Denzel, A., Gilmour, K.C., Rosewell, I.R., Stamp, G.W., Beddington, R.S., Mundlos, S., Olsen, B.R., et al. (1997). Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89, 765-771. https://doi.org/10.1016/S0092-8674(00)80259-7
  15. Sadikovic, B., Thorner, P., Chilton-Macneill, S., Martin, J.W., Cervigne, N.K., Squire, J., and Zielenska, M. (2010). Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer 10, 202. https://doi.org/10.1186/1471-2407-10-202
  16. Salto-Tellez, M., Peh, B.K., Ito, K., Tan, S.H., Chong, P.Y., Han, H.C., Tada, K., Ong, W.Y., Soong, R., Voon, D.C., et al. (2006). RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene 25, 7646-7649. https://doi.org/10.1038/sj.onc.1209739
  17. Tsunematsu, T., Kudo, Y., Iizuka, S., Ogawa, I., Fujita, T., Kurihara, H., Abiko, Y., and Takata, T. (2009). RUNX3 has an oncogenic role in head and neck cancer. PLoS One 4, e5892. https://doi.org/10.1371/journal.pone.0005892
  18. Whittle, M.C., Izeradjene, K., Rani, P.G., Feng, L., Carlson, M.A., DelGiorno, K.E., Wood, L.D., Goggins, M., Hruban, R.H., Chang, A.E., et al. (2015). RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma. Cell 161, 1345-1360. https://doi.org/10.1016/j.cell.2015.04.048

피인용 문헌

  1. Role of the runt‐related transcription factor (RUNX) family in prostate cancer vol.288, pp.21, 2020, https://doi.org/10.1111/febs.15804